Eli Lilly and Company vs Ligand Pharmaceuticals Incorporated: Annual Revenue Growth Compared

Eli Lilly vs Ligand: A Decade of Revenue Growth

__timestampEli Lilly and CompanyLigand Pharmaceuticals Incorporated
Wednesday, January 1, 20141961560000064538000
Thursday, January 1, 20151995870000071914000
Friday, January 1, 201621222100000108973000
Sunday, January 1, 201722871300000141102000
Monday, January 1, 201821493300000251453000
Tuesday, January 1, 201922319500000120282000
Wednesday, January 1, 202024539800000186419000
Friday, January 1, 202128318400000277133000
Saturday, January 1, 202228541400000196245000
Sunday, January 1, 202334124100000131314000
Monday, January 1, 202445042700000
Loading chart...

Data in motion

A Tale of Two Pharmaceutical Giants: Revenue Growth from 2014 to 2023

In the competitive world of pharmaceuticals, Eli Lilly and Company and Ligand Pharmaceuticals Incorporated have charted distinct paths over the past decade. From 2014 to 2023, Eli Lilly's revenue surged by approximately 74%, reflecting its robust market strategies and innovative product lines. In contrast, Ligand Pharmaceuticals, while smaller in scale, demonstrated a commendable growth of around 103% during the same period, showcasing its agility and niche focus.

Eli Lilly's revenue growth was particularly notable in 2023, reaching a peak of $34.1 billion, a testament to its sustained market leadership. Meanwhile, Ligand's revenue, though modest in comparison, peaked in 2021 at $277 million, highlighting its strategic partnerships and licensing deals. This comparison underscores the diverse strategies employed by pharmaceutical companies to thrive in a dynamic industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025